Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Takeda Pharmaceutical Company Limited expected to post earnings of JPY134.54 a share - Earnings Preview

By Reuters News

  • Takeda Pharmaceutical Company Limited , is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2026

  • The Chuo-ku Tokyo-to-based company is expected to report a 5.6% increase in revenue to JPY1.175 trillion from JPY1.11 trillion a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Takeda Pharmaceutical Company Limited is for earnings of JPY134.54 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Takeda Pharmaceutical Company Limited is $21.90, about 7.2% above its last closing price of $20.43

This summary was machine generated October 27 at 06:16 GMT. All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.